YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Zymeworks Inc. Acquisition diversifies durable cash flows and advances Zymeworks' strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI® expected to contribute immediately accretive revenu…
Investing.com -- B. Riley analyst Mayank Mamtani has identified top biotech picks heading into third-quarter 2026 earnings season, following the Federal Reserve's 25 basis point rate hike to 4.00%, its first increase since July 2023. The u…
[Reciprocal Tariffs] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - SEPTEMBER 14 * VOLATILITY WAT…
Jazz Pharmaceuticals JAZZ announced second interim top-line overall survival (OS) results from the phase III HERIZON-GEA-01 study, which evaluated different combination regimens involving its marketed drug, Ziihera (zanidatamab) as a first…
Jazz Pharmaceuticals JAZZ announced that the FDA has approved a label expansion of its marketed drug, Ziihera (zanidatamab-hrii), for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroe…
Medical research ©rawpixel Zymeworks (NASDAQ:ZYME) shares climbed nearly 4.0% in pre-market trading as investors positioned themselves ahead of an important U.S. regulatory decision on zanidatamab, expected the following day. The FDA's PDU…
Theravance Biopharma TBPH reported second-quarter 2026 adjusted earnings of 19 cents per share, matching the Zacks Consensus Estimate. In the year-ago quarter, the company had incurred an adjusted loss of 8 cents per share. Total revenues…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Zymeworks (ZYME [https://seekingalpha.com/symbol/ZYME]) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list. * The bank sees shares rising due to…
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biothera…
Zymeworks Inc. (NASDAQ:ZYME) is one of the best small cap stocks to buy with the highest upside potential. Truist lifted the price target on Zymeworks Inc. (NASDAQ:ZYME) to $31 from $28 on July 7 and maintained a Buy rating on the shares.…
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Zymeworks Inc. (NASDAQ:ZYME) is one of the best biotech stocks on this list. TheFly reported on June 9 that Truist Securities initiated coverage of ZYM…
Shares of Theravance Biopharma TBPH sank by around 3% on June 29, 2026, after the company announced a definitive agreement with Zymeworks Inc. ZYME under which the latter will acquire TBPH in an all-cash transaction valued at approximately…
Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m (C$1.32bn). Under the terms of the deal, Theravance Biopharma shareholders will receive $1…
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression levelConfirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian c…
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.47 per share, beating the Zacks Consensus Estimate of $4.23 per share. This compares to earnings of $4.06 per share a year ago. These figures are adjusted for non-recurri…
Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 30% increase over the past year with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be tra…
Key Points Acquired 687,600 shares of Axogen; estimated trade size of $22.36 million based on quarterly average pricing Quarter-end stake value rose by $22.78 million, reflecting both the new position and price changes Transaction represen…
What happened According to a recent SEC filing, Capricorn Fund Managers Ltd initiated a new stake in Axogen(NASDAQ:AXGN) during the first quarter of 2026. The fund acquired 687,600 shares, with an estimated transaction value of $22.36 mill…
What happened According to an SEC filing dated April 24, 2026, Capricorn Fund Managers reduced its stake in Waystar(NASDAQ:WAY) by 692,554 shares during the first quarter of 2026. The estimated transaction value was $18.38 million, calcula…
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Wilson's Disease, Ovaria…
(RTTNews) - Zymeworks Inc. (ZYME) presented new Phase 1 data for its folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), ZW191 at the AACR Annual Meeting 2026. The therapy demonstrated encouraging anti-tumor activity in he…
ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expressionConfirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum resistant ovarian canc…
Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple solid tumor m…
(RTTNews) - Delaware-based biotechnology company Zymeworks Inc. (ZYME) Wednesday announced the appointment of Kristin Stafford as Chief Financial Officer. Shares of Zymeworks are gaining 0.66 points or 2.64 percent in the pre-market sessio…
Zymeworks Inc. VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifu…
(RTTNews) - Zymeworks Inc.'s (ZYME) investigational drug ZW191 has been granted Fast Track designation by the FDA for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer. Shares are up over 3% at $24.73…
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, region…
Zymeworks Inc. Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company manag…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Zymeworks (NasdaqGS:ZYME) reported positive Phase 3 results for partnered HER2 antibody zanidatamab. The company indicated i…
Earnings Call Insights: Zymeworks Inc. (ZYME) Q4 2025 MANAGEMENT VIEW * Kenneth Galbraith, Chairman, CEO, Acting CFO & President, opened by highlighting the Phase III HERIZON-GEA-01 trial results: "Zanidatamab in combination with chemother…
This article first appeared on GuruFocus. Total Revenue: $106 million for 2025, up from $76.3 million in 2024. Operating Expenses: $198.5 million for 2025, down from $213.4 million in 2024. Net Loss: $81.1 million for 2025, compared to $12…
Zymeworks logo Zymeworks Offers Hope for More than Just Long-Term Investors Zymeworks (NASDAQ:ZYME) executives used the company’s fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidatam…
Zymeworks Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Asset Optimization Management attributes the strong clinical foundation to the Phase 3 HORIZON-GEA-01 trial results, where zanidatumab demonstrated a median over…
(RTTNews) - Zymeworks Inc. (ZYME) has reported its fourth-quarter and full-year 2025 financial results while announcing a major $250 million royalty-backed financing agreement with Royalty Pharma, strengthening its balance sheet and extend…
(RTTNews) - Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX), a buyer of biopharmaceutical royalties, through a non-recourse r…